Stay updated with breaking news from Isabelle Ghellynck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Patients with axial spondyloarthritis (axSpA), who achieve sustained remission, benefit from continued CIMZIA (certolizumab pegol) treatment either at the full or reduced maintenance dose
About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people operating in ~ 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news Forward looking statements – UCB This press release contains forward-looking statements including, without limit...
(2) - Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable - UCB invested €25 million ($29.3 million) and as majority shareholder, will sit on the Board of Directors of Nile with future opportunities to acquire insights and data from Nile's platform BRUSSELS and ATLANTA, Jan. 13, 2021 /PRNewswire/ -- UCB today announced the launch of Nile AI, Inc., a new independent company created to improve care for people living with epilepsy, their caregivers, and healthcare providers (HCPs). Nile was founded with a clear mis...